Ticker
ABEO

Price
4.51
Stock movement up
+0.15 (3.44%)
Company name
Abeona Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
26.49M
Ent value
29.89M
Price/Sales
7.92
Price/Book
0.84
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
257.94%
3 year return
33.87%
5 year return
-12.41%
10 year return
-15.57%
Last updated: 2022-08-25

DIVIDENDS

ABEO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales7.92
Price to Book0.84
EV to Sales8.93

FINANCIALS

Per share

Loading...
Per share data
Current share count5.87M
EPS (TTM)-0.86
FCF per share (TTM)-0.66

Income statement

Loading...
Income statement data
Revenue (TTM)3.35M
Gross profit (TTM)3.35M
Operating income (TTM)-95.83M
Net income (TTM)-89.72M
EPS (TTM)-0.86
EPS (1y forward)-2.53

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-2864.02%
Profit margin (TTM)-2681.56%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash20.33M
Net receivables0.00
Total current assets39.20M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets55.17M
Accounts payable1.60M
Short/Current long term debt9.10M
Total current liabilities12.34M
Total liabilities23.73M
Shareholder's equity31.44M
Net tangible assets31.44M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-65.77M
Capital expenditures (TTM)3.81M
Free cash flow (TTM)-69.58M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-285.36%
Return on Assets-162.63%
Return on Invested Capital-269.73%
Cash Return on Invested Capital-209.16%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open4.37
Daily high4.67
Daily low4.35
Daily Volume149K
All-time high47188.00
1y analyst estimate46.67
Beta1.24
EPS (TTM)-0.86
Dividend per share-
Ex-div date31 Mar 2000
Next earnings date14 Nov 2022

Downside potential

Loading...
Downside potential data
ABEOS&P500
Current price drop from All-time high-99.99%-12.18%
Highest price drop-100.00%-56.47%
Date of highest drop17 Jun 20229 Mar 2009
Avg drop from high-91.92%-11.38%
Avg time to new high399 days12 days
Max time to new high7457 days1805 days
COMPANY DETAILS
ABEO (Abeona Therapeutics Inc) company logo
Marketcap
26.49M
Marketcap category
Small-cap
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Employees
90
Investor relations
-
SEC filings
CEO
Joao Siffert
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside...
22. september 2022
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel di...
13. september 2022
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring...
11. august 2022
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 inf...
20. juli 2022
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
24. juni 2022
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
8. juni 2022
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patient...
6. juni 2022
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is schedu...
6. juni 2022
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
1. juni 2022
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
31. mai 2022
Next page